Press Release | NeoGenomics Laboratories

February 23, 2022

NeoGenomics Reports Full Year Revenue of $484 Million and $126 Million for the Fourth Quarter of 2021

February 14, 2022

NeoGenomics appoints Dr. Shashi Kulkarni, a World-Renowned Oncology Genomics Expert, and Innovator as Chief Scientific Officer

February 11, 2022

NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Publish Positive Results from Prospective Clinical Study of RaDaR(TM) in Head and Neck Squamous Cell Carcinoma

February 8, 2022

NeoGenomics to Participate Virtually in Multiple Upcoming Institutional Investor Conferences

February 2, 2022

NeoGenomics Schedules its Fourth Quarter and Full Year 2021 Earnings Release for February 23, 2022

January 24, 2022

NeoGenomics First to Partner with Biomarker Collaborative and Deliver Patient Resources Along with Oncology Testing Results

January 11, 2022

NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program

December 13, 2021

NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients